Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy

Annals of Oncology

Volumn 25, Issue 5, 2014, Pages 992-998

  Bane, A L ^a,b   Whelan, T J ^b   Pond, G R ^b   Parpia, S ^b   Gohla, G ^a   Fyles, A W ^a   Pignol, J P ^a   Pritchard, K I ^c   Chambers, S ^b   Levine, M N ^b  

^a Department of Pathology and Molecular Medicine ^*

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

biomarker; breast cancer; hypofractionated radiotherapy; randomized controlled trial

Indexed keywords

TUMOR MARKER;

ADJUVANT THERAPY; BREAST NEOPLASMS; CELL HYPOXIA; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODEL; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; SEGMENTAL MASTECTOMY; TREATMENT OUTCOME;

BREAST NEOPLASMS; CELL HYPOXIA; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84902465482     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu090     Document Type: Article

References (20)

1. Harvey, J.M., Clark, G.M., Osborne, C.K., et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17 (1999), 1474–1481.
2. Paik, S., Shak, S., Tang, G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 (2004), 2817–2826.
3. Slamon, D., Eiermann, W., Robert, N., et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365 (2011), 1273–1283.
4. Whelan, T.J., Pignol, J.P., Levine, M.N., et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 362 (2010), 513–520.
5. Smith, B.D., Bentzen, S.M., Correa, C.R., et al. Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys 81 (2011), 59–68.
6. BLOOM, H.J., RICHARDSON, W.W., Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11 (1957), 359–377.
7. Jones, H.A., Antonini, N., Hart, A.A., et al. Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol 27 (2009), 4939–4947.
8. Sorlie, T., Tibshirani, R., Parker, J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100 (2003), 8418–8423.
9. Carlson, D.J., Keall, P.J., Loo, B.W. Jr, et al. Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia. Int J Radiat Oncol Biol Phys 79 (2011), 1188–1195.
10. Elston, C.W., Ellis, I.O., Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19 (1991), 403–410.
11. Haviland, J.S., Owen, J.R., Dewar, J.A., et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 14 (2013), 1086–1094.
12. Nguyen, P.L., Taghian, A.G., Katz, M.S., et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26 (2008), 2373–2378.
13. Voduc, K.D., Cheang, M.C., Tyldesley, S., et al. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28 (2010), 1684–1691.
14. Arvold, N.D., Taghian, A.G., Niemierko, A., et al. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol 29 (2011), 3885–3891.
15. Colleoni, M., Cole, B.F., Viale, G., et al. Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Clin Oncol 28 (2010), 2966–2973.
16. Turner, N.C., Reis-Filho, J.S., Russell, A.M., et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26 (2007), 2126–2132.
17. Abdulkarim, B.S., Cuartero, J., Hanson, J., et al. Increased risk of locoregional recurrence for women with T1–2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol 29 (2011), 2852–2858.
18. Semenza, G.L., Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29 (2010), 625–634.
19. Buffa, F.M., Harris, A.L., West, C.M., et al. Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer 102 (2010), 428–435.
20. Simon, R.M., Paik, S., Hayes, D.F., Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101 (2009), 1446–1452.